There are two types of essential fatty acids (EFAs), the n-6 derived from linoleic acid and the n-3 from alpha-linolenic acid. They play major roles in the structure of all organs and determine some of the properties of all membranes. The EFAs also act as precursors for the eicosanoids, the prostaglandins and leukotrienes. The body requires adequate intakes of linoleic and alpha-linolenic acids but must also be able to metabolize them normally. Abnormalities of EF A intake and absorption are exceedingly rare except in patients with known malabsorption or who are on total parenteral nutrition. Abnormalities of EFA metabolism, in contrast, appear to be rather common. Patients with atopic eczema seem to have a defect at the delta-6-desaturase level which leads to elevated blood levels of the two main dietary precursors but significantly reduced levels of all metabolites. Patients with premenstrual syndrome appear to have low n-6 metabolites and elevated n-3 metabolites, those with premenstrual breast disease to have low n-6 and near normal n-3 metabolites and those with non-cyclic breast disease to have a deficiency of both n-6 and n-3 acids. Both diabetes and alcoholism lead to defective delta-6-desaturase function and low concentrations of EFA metabolites. There is considerable clinical evidence that gamma-linolenic acid can correct some of the abnormalities in EFA patterns and can also lead to simultaneous clinical improvement, suggesting that the EFA abnormalities are playing a causative role. As Sinclair predicted 30 years ago, understanding of EFA metabolism seems likely to bring about major practical advances in clinical medicine.
INTRODUCTION
The essential fatty acids (EFAs) were discovered by Burr and Burr (1930) . There are now known to be two series of EFAs, the n-6 series derived from linoleic acid, and the n-3 series derived from alpha-linolenic acid. The metabolic pathways are outlined in Figure 1 .
The main EFAs in the diet are linoleic and alpha-linolenic. There are substantial amounts of arachidonic acid in meat and eggs and some sea foods such as certain shrimps. Gamma-linolenic acid (GLA), dihomogammalinolenic acid (DGLA) and arachidonic acid are found in substantial amounts in human milk but in only very tiny amounts in cows' milk. The longer chain fatty acids of the n-3 series, notably eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are found in oils of marine origin.
It is usually stated that the minimum daily requirement for linoleic acid is 1% of daily calorie intake (Mead and Fulco, 1976; Kunau and Holman, 1977 ). An FAO/WHO report (1977) suggested higher intakes of 3% of total calorie intake for normal adults and 5% for children and pregnant and lactating women. In the Western World these amounts are comfortably exceeded in almost all 127 diets. The increasing uses of vegetable oils in foods and the strong recommendations from many official medical bodies that polyunsaturated fat intake should be increased, have led to this situation. A possible confounding factor which has not been fully explored is that EF As in natural vegetable oils have their double bonds in the cis conformation. All cis fatty acids have EPA activity. The cis bonds are relatively unstable, and in order to improve stability, manufacturers often process the oils to convert cis to the more stable trans bonds (Enig et al., 1978) . Trans acids can competitively inhibit EPA metabolism and it is possible that the effective intake of linoleic acid is less than usually estimated. Surprisingly little is known about the n-3 EF As and doubts have been cast on their essentiality in humans. However they are found in large amounts in the brain, the retina, the gonads and the phospholipids of all cell membranes. It is unlikely that these large amounts have no function. Because alpha-linolenic acid has three double bonds, it is relatively less stable than linoleic acid and is a particular target of food processors wishing to make their end products more stable. As a result, and also as a result of declining consumption of fish by many individuals, some have argued that there has been a sharp fall in the intake of n-3 EFAs in recent decades (Rudin, 1981) .
Four of the EFAs, DGLA, arachidonic acid, adrenic acid and EPA, are known to give rise to prostaglandins (PGs). PGs, formed by a cyclo-oxygenase enzyme system, and the other major biologically active eicosanoids, the leukotrienes, formed by a lipoxygenase initiated enzyme sequence, have been the subject of immense attention during the past few years. As a result there is a tendency to view the biological roles of EF As purely in terms of their eicosanoid precursor role. This is almost certainly a serious error. Without in any sense downplaying the importance of the eicosanoids, it is vital to emphasise the structural role of 128 the EFAs in all phospholipids and therefore in all cell membranes. The analysis of red cell membrane phospholipids shown in Table 1 indicates the importance of the long chain C-22 EFAs. And this shuctural role has major implications for function. The presence of substantial amounts of highly unsaturated fatty acids determines the fluidity and flexibility of cell membranes and in tum their permeability and the functioning of membrane bound receptors and enzymes. Thus the EFAs are involved in the modulation of every aspect of function, probably being especially important in tissues such as nerve, muscle and immune system where membrane properties are key factors in determining responsiveness. Significantly different from control at: *p<O.OS; **p<O.Ol; ***p<0.001
There were 50 normal individuals and 34 alcoholics. Each value represents the mean ± SD. Each fatty acid concentration is expressed as a percentage of the total fatty acids present in the phospholipid fraction. 18:3n-6, 18:3n-3, 18:4n-3 and 20:4n-3 were present in only trace amounts and are not shown. Also shown are the saturated fats 16:0 (palmitic) and 18:0 (stearic) and the monounsaturated fatty acid, oleic (18:1n-9).
Analysis of the red cell membrane illustrates another important aspect of EFA biology. Although the major dietary EFAs are linoleic and alpha-linolenic acids, it is their metabolites which seem to play the major role in most tissues. This reaches an extreme state in brain where linoleic and alpha-linolenic acids form less than 1% of the fatty acids present whereas their metabolites are there in great abundance. The eicosanoid precursors are also, of course, all metabolites. This means that the ability of the body to utilise the dietary sources of EFAs and to metabolize them further becomes of major significance. This is particularly well illustrated by the cat, an animal which appears to lack the delta-6desturase which converts linoleic acid to gamma-linolenic acid. In this animal linoleic acid does not work as an EF A whereas GLA has strong EF A activity (Frankel and Rivers, 1978) .
It is generally believed, though without conclusive proof, that the enzyme sequence which metabolizes the n-6 and the n-3 EFAs is the same. The sequence appears to have greater affinity for the n-3 compounds, so that other things being equal they will be preferentially metabolized.
EFAS IN DISEASE
Textbooks of nutrition state that EFA deficiency does not occur in humans except under highly unusual circumstances such as prolonged total parenteral 129 nutrition without lipids in the fluid, or the administration to infants of artificial milk without EFAs. There are many case reports of these unusual circumstances: the patients have often developed skin problems akin to eczema and have had unsatisfactory wound healing.
On the other hand, many organizations involved with cardiovascular medicine, such as the American Heart Association (Grundy et al., 1982) have long advocated what amount to megadoses of EFAs for those at risk of cardiovascular disease. This is the only example of which I am aware in which orthodox medicine advocates intakes of an essential nutrient many, many times higher than the minimum daily requirement. For many years, Sinclair was an isolated voice in arguing that problems of EF A metabolism were involved not only in cardiovascular medicine but in a variety of other conditions (Sinclair, 1958) . Recent work suggests that Sinclair's views, long regarded as heresy, may have a solid basis.
The one exception to the general rule about intake and absorption of EF As being adequate by the usual standards is in patients with various forms of malabsorption. Any problem with lipid absorption is likely to lead to low levels of linoleic acid in the blood, even though actual intake may be satisfactory. Over the last two years we have analysed plasma samples from some 3000 patients with a wide variety of pathological conditions. We have almost never found unusually low levels of either linoleic acid or alpha-linolenic acid, except in a group of patients who had lost long sections of their intestines, usually through trauma. These patients had low levels of linoleic acid but normal levels of linoleic acid metabolites indicating that they were compensating for inadequate absorption by increased conversion to the various metabolites which play so many roles in the body.
What we have found, however, are a number of patterns of abnormality of the metabolites of linoleic acid and alpha-linolenic acid. While a true dietary deficiency of EFAs may be one of the rarest nutritional problems, abnormal EF A processing may be one of the commonest human biochemical abnormalities. This will be illustrated by various examples. Brown and Hansen (1937) first drew attention to the possible role of EFAs in eczema. Using the crude methods available at the time they found that EFA levels were low in the blood of eczema patients and that feeding large amounts of linoleic acid could raise linoleic acid but not arachidonic acid levels to normal. The pathway of EFA metabolism was then unknown, but with hindsight it can be seen that this finding implied defective conversion of linoleic acid to arachidonic.
ATOPIC ECZEMA
We have recently confirmed and extended Hansen's findings. In a study performed in conjunction with the Department of Dermatology at Bristol University Medical School, we found that concentrations of linoleic and alphalinolenic acids were actually elevated in the plasma phospholipids of patients with atopic eczema, concentrations of the metabolites of both the n-6 and n-3 pathways were highly significantly reduced (Table 2) . This suggests that atopies may have a defect in the delta-6-desaturase which converts linoleic acid to GLA and alpha-linolenic acid to 18:4n-3 (Manku et al., 1982) . By-passing this defect with regard to the n-6 EFAs by administering GLA directly led to significant, dose-related improvement in the clinical condition (Wright and Burton, 1982) . GLA was administered in the form of Efamol, evening primrose oil from a variety of Oenothera biennis bred to yield oil of constant composition. This clinical response suggests that the EFA abnormality is not merely associated with atopy but is actually a cause of at least some of the clinical problems. We 130 have proposed that atopic individuals have a minor inborn error of metabolism such that their delta-6-desaturase functions less efficiently than normal. This would lead to low levels of the metabolites, including the PG precursors. This proposal could explain the protection against atopy achieved by breast feeding: breast milk, but not artificial formulae, contains GLA and DGLA which could by-pass such a bottleneck. It could also account for the susceptibility of many atopies to severe reactions from non-steroidal anti-inflammatory drugs which inhibit the conversion of EFAs to PGs. 3.06 ± 0.60 2.63 ± 0.52 ** 2.79 ± 0.64 * 2.43 ± 0.11 ** 2.54 ± 0.14 ** 20.4n-6 11.36 ± 1.67 6.75 ± 1.12 ** 9.34 ± 1.40 ** 8.10 ± 0.48 ** 7.69 ± 0.36 ** 22:4n-6 0.73 ± 0.26 0.38 ± 0.24 ** 0.53 ± 0.33 ** 0.23 ± 0.05 ** 0.33 ± 0.05 ** 22:5n-6
1.12 ± 0.67 0.13 ± 0.09 ** 0.36 ± 0.81 ** 0.54 ± 0.07 ** 0.73 ± 0.09 ** 3.54 ± 0.89 2.43 ± 0.62 ** 4.20 ± 0.91 ** 3.10 ± 0.18 2.28 ± 0.15 ** Results are expressed as percentages of the total fatty acids present and are shown as means ± SD (normals, eczema and premenstrual syndrome) or SEM (breast disease).
Differences from control were analysed by Student's t test:* represent p<0.05, **p<0.01 or better.
Related to this issue is the problem of hyperactivity in children. Textbooks of dermatology frequently comment on the hyperactive behaviour of atopic children. The great majority of children who present for help with hyperactivity turn out to be also atopic (Colquhoun and Bunday, 1981) . Colquhoun and Bunday also noted that hyperactive children are very often exceptionally thirsty. This also probably points towards an EF A problem because greatly increased trans-epidermal water loss is one of the cardinal features of EFA deficiency. Administration of GLA to large numbers of hyperactive children has led to substantial relief in many of them.
It therefore seems possible that atopy may be an inborn error of lipid metabolism. This has major implications both for the core atopic disorders of eczema, asthma and allergic rhinitis and for the large number of illnesses which are known to present more often than expected in atopies. These include migraine, otitis media, premenstrual syndrome, Crohn's disease, nephrotic syndrome, multiple sclerosis and possibly cardiovascular disease.
MENSTRUAL CYCLE AND BREAST DISEASES
The premenstrual syndrome and non-malignant diseases of the breast are of great interest because they illustrate the concept that EFA abnormalities may be within the n-6 series alone or may involve both types of EFA. Table 2 shows the n-6 and n-3 EFAs in women with classical multi-symptom premenstrual syndrome, in women with breast problems confined to the premenstrual period and in women with non-cyclical breast lumps and pain. All three groups have, like the eczema patients, normal or slightly elevated concentrations of linoleic acid and reduced levels of linoleic acid metabolites. In contrast, they differ 131 strikingly in the n-3 pattern. The women with classical pre-menstrual syndrome have elevated n-3 EFA concentrations, the women with premenstrual breast disease have slightly reduced n-3 levels, while the women with non-cyclical breast disease have highly significantly reduced n-3 EFAs.
Administration of GLA as Efamol had a dramatic effect in relieving premenstrual syndrome (Brush, 1983) a rather good effect in relieving premenstrual breast disease (Preece et al., 1983) but little effect in relieving non-cyclical breast disease (Preece et al., 1983) . Since Efamol contains only n-6 acids these clinical findings correlate well with the idea that the EF A abnormalities are playing a causative role. A deficiency purely or primarily of n-6 EFAs responds to n-6 supplementation, while a combined deficiency does not. Studies are at present beginning to test the possibility that when there is a combined deficiency, combined treatment will help.
The bases for the EFA abnormality in these conditions are unknown. There is a high frequency of atopy in the premenstrual syndrome (Atton-Chamla et al., 1980) and it may be that this syndrome should be added to the manifestations of atopy. However the syndrome seems considerably commoner than atopy and other factors must also be involved.
INDUCED ABNORMALITIES OF EFA METABOLISM -ALCOHOLISM AND DIABETES
Many years ago animal studies showed that diabetes mellitus lead to reduced conversion of linoleic acid to GLA (Mercuri et al., 1966) . Deficient conversion of linoleic acid to arachidonic acid has now been shown in human diabetics Ganes et al., 1983) . Very large doses of linoleic acid may help to overcome such a partial block and in a controlled trial over five years the administration of such large doses to diabetics sharply reduced the incidence of complications and improved glucose metabolism (Houtsmuller et al., 1982) . Another situation in which EFA metabolism is disturbed is alcoholism since alcohol has been shown to inhibit the activity of the delta-6-desaturase (Nervi et al., 1980) . In a study carried out in conjunction with Craig Dunain Hospital in Inverness, we have found severe disruption of EFA metabolism in alcoholics. Table 1 shows that while linoleic and alpha-linolenic concentrations are normal or near normal, those of the metabolites of both are highly significantly reduced. Administration of Efamol to alcoholics undergoing withdrawal led to more rapid normalization of liver function and less tranquillizer use than in alcoholics on placebo. At the same time there was also a significant normalization of EFA levels as compared to the placebo group. (Glen et al., 1983) Since EFAs appear to be of major importance in the structure and function of brain and liver, it is possible that many of the adverse effects of ethyl alcohol may be related to its disruption of EFA metabolism.
CARDIOVASCULAR DISORDERS
The traditional reasons for the recommendation of a high EF A intake by the medical profession are lowering of cholesterol, inhibition of platelet aggregation and reduction of arterial pressure. There is evidence from both animal and human studies that aging may lead to a reduced ability to convert linoleic to gamma-linolenic acid (Ayala et al., 1973; Darcet et al., 1980) . If so, this may be one reason why such inordinately high intakes of linoleic acid are officially recommended by many authorities. The high levels of linoleic acid may be required to overcome this bottleneck. We have recently found that GLA has dramatically greater effects than linoleic acid in lowering cholesterol levels (Horrobin and Manku, 1983) . This means that linoleic acid must probably be 132 converted to GLA and beyond in order to lower cholesterol levels, and also
